260 related articles for article (PubMed ID: 30694399)
1. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST.
Goldfarb L; Duchemann B; Chouahnia K; Zelek L; Soussan M
EJNMMI Res; 2019 Jan; 9(1):8. PubMed ID: 30694399
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
Kaira K; Yamaguchi O; Naruse I; Umeda Y; Honda T; Watanabe S; Ichikawa K; Yanagisawa S; Kasahara N; Higuchi T; Hashimoto K; Miura Y; Shiono A; Mouri A; Imai H; Iizuka K; Ishizuka T; Minato K; Suda S; Kagamu H; Mori K; Seki N; Kuji I
Cancer Imaging; 2023 Mar; 23(1):23. PubMed ID: 36859341
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of [
Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
[TBL] [Abstract][Full Text] [Related]
4. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
Park S; Lee Y; Kim TS; Kim SK; Han JY
Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Squamous Cell Carcinoma Subjected to Anti PD-1 Immunotherapy: Monitoring Response Through Serial PET/CT Scans with
Filippi L; Proietti I; Petrozza V; Bagni O; Schillaci O
Cancer Biother Radiopharm; 2022 Apr; 37(3):226-232. PubMed ID: 35128935
[No Abstract] [Full Text] [Related]
6. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
7. Role of serial F-18 FDG PET/CT scans in assessing treatment response and predicting relapses in patients with symptomatic sarcoidosis.
Maturu VN; Rayamajhi SJ; Agarwal R; Aggarwal AN; Gupta D; Mittal BR
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):372-380. PubMed ID: 28079849
[TBL] [Abstract][Full Text] [Related]
8. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
[TBL] [Abstract][Full Text] [Related]
9. Predictive value and accuracy of [
Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
[TBL] [Abstract][Full Text] [Related]
10. Early
Chen A; Mokrane FZ; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Dulery R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Armand P; Houot R; Dercle L
J Nucl Med; 2020 May; 61(5):649-654. PubMed ID: 31628220
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
13. Assessment of early metabolic progression in melanoma patients under immunotherapy: an
Sachpekidis C; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
EJNMMI Res; 2021 Sep; 11(1):89. PubMed ID: 34495433
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
[TBL] [Abstract][Full Text] [Related]
15.
Humbert O; Cadour N; Paquet M; Schiappa R; Poudenx M; Chardin D; Borchiellini D; Benisvy D; Ouvrier MJ; Zwarthoed C; Schiazza A; Ilie M; Ghalloussi H; Koulibaly PM; Darcourt J; Otto J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1158-1167. PubMed ID: 31760467
[TBL] [Abstract][Full Text] [Related]
16. Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods.
Ayati N; Lee ST; Zakavi SR; Cheng M; Lau WFE; Parakh S; Pathmaraj K; Scott AM
J Nucl Med; 2021 Jul; 62(7):926-933. PubMed ID: 33246978
[TBL] [Abstract][Full Text] [Related]
17. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
18. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H
Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
[TBL] [Abstract][Full Text] [Related]
19. Tumor response assessment on imaging following immunotherapy.
Berz AM; Dromain C; Vietti-Violi N; Boughdad S; Duran R
Front Oncol; 2022; 12():982983. PubMed ID: 36387133
[TBL] [Abstract][Full Text] [Related]
20. Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT.
Kitajima K; Maruyama M; Yokoyama H; Minami T; Yokoi T; Nakamura A; Hashimoto M; Kondo N; Kuribayashi K; Kijima T; Hasegawa S; Yamakado K
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]